Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

Mon, 22nd Feb 2021 08:47

(Alliance News) - Stock prices in Europe started the new week on a low ebb with sentiment damped by concerns that an acceleration in inflation could spell an end to stimulus measures.

In the UK, focus will be on Prime Minister Boris Johnson, who is set to present a roadmap to exit lockdown in England.

The flagship FTSE 100 index was down 51.02 points, or 0.8%, at 6,573.00 early Monday. The domestic-focused FTSE 250 index was down 212.49 points, or 1.0%, at 20,823.47, and the AIM All-Share index was down 7.34 points, or 0.6%, at 1,206.84.

The Cboe UK 100 index was down 1.3% at 652.33 points. The Cboe 250 was down 1.1% at 18,388.39, but the Cboe Small Companies was marginally higher at 12,801.41.

The CAC 40 index in Paris was down 0.8% and Frankfurt's DAX 30 was 0.9% lower.

"It's one of these days where investors don't know what to do with the good news. Asian markets kicked off the week on a flat-to-negative note despite the most-expected news that the immunization with Pfizer and BioNTech's Covid vaccines do curtail the transmission of the coronavirus. In other words, it means that the Covid vaccines will actually be the game changer in 2021," Swissquote analyst Ipek Oykardeskaya commented.

"But it also means that the huge monetary and fiscal stimulus will be harder to justify, and companies will need to fly with their own wings. The major worry is that the rising inflation worries could accelerate the end of the stimulus game."

In London, miner and commodities broker Glencore was among the better-performing large-caps stocks, up 1.2%. JPMorgan raised Glencore to Overweight from Neutral.

International Consolidated Airlines Group climbed 0.4% as the British Airways parent announced the UK flag carrier has secured two finance-support pacts worth GBP2.45 billion in total.

BA has secured a GBP2.0 billion UK Export Development Guarantee of GBP2.0 billion. The term-loan is for five years. British Airways also agreed a deferral of GBP450 million in pension deficit contributions that were due from October last year to September this year.

Among mid-caps, Mitchells & Butlers fell 1.3% as it noted a sharp fall in sales in recent months and launched an open offer to bolster the pub operator's finances.

Mitchells & Butlers announced a GBP351 million open offer of shares to bolster its balance sheet as its "liquidity position has deteriorated significantly as a result of the impact of the Covid-19 pandemic".

The All Bar One owner said the extra cash will go towards reducing its unsecured debt. It also will support its secured debt financing.

Since the end of December, none of M&B's sites have been open. In the period between, September 27 and January 16, total managed sales were 70% lower annually.

Pubs, airlines and the wider travel & leisure industry will be in focus Monday as UK PM Johnson outlines how the Covid-19 curbs will be eased, paving the way for the first easing of restrictions since England's third national lockdown was announced on January 4.

All pupils in all years can go back to the classroom from March 8, with outdoor after-school sports and activities allowed to restart as well, Johnson is expected to say.

Socialising in parks and public spaces with one other person also will be permitted in a fortnight when the rules are relaxed to allow people to sit down for a drink or picnic.

However, Number 10 insisted that the "stay at home" message would remain in place despite the relaxation of some restrictions.

Sterling slipped below the USD1.40 mark as the dollar was higher across the board early Monday. The pound was quoted at USD1.3996, down slightly from USD1.4020 at the London equities close Friday.

The euro also lost ground on the dollar over the weekend. The euro stood at USD1.2104 early Monday, down from USD1.2139 at the European equities close Friday. Against the yen, the dollar was trading at JPY105.79, improved from JPY105.53.

Back in London, fund supermarket Hargreaves Lansdown and trading platform AJ Bell were down 0.9% and 1.9%, respectively.

AJ Bell, Hargreaves Lansdown, and Interactive Investor have all written to the UK Treasury complaining about their exclusion from a majority of initial public offerings.

The heads of the three companies wrote to City minister John Glen last week asking that he consider forcing companies to consider retail offers in new flotations as well as the opening of a wider consultation.

The letter noted that smaller investors has been unable to buy into the recent IPOs from online personalised cards and gifts retailer Moonpig Group, as well as shoe maker Dr Martens and Hut Group owner THG.

In all three cases, share prices for the companies rose to an instant premium to the IPO price, forcing private investors to pay more hefty amounts for shares.

"As it stands, retail shareholder rights are almost completely ignored when it comes to the vast majority of IPOs, which largely take place between City institutions behind closed doors," the letter said.

Elsewhere in London, G4S shed 9.7% and was trading at 243.00 pence per share.

Security company GardaWorld "stands firm" and its 235p per share offer for G4S is final. GardaWorld said early Monday the offer will not be revised.

"There can be no better owner for G4S than GardaWorld, but we are disciplined buyers and we will not overpay for a company with systemic ESG issues that continue to come to light," GardaWorld Chief Executive Stephan Cretier said.

The 235p offer values G4S at GBP3.68 billion.

Earlier in February, London's Takeover Panel stepped in to put in place an auction procedure to resolve an ongoing takeover saga.

Last month, G4S agreed to be taken over by Allied Universal in a GBP3.8 billion deal, but the 245p cash offer has been extended and remains open for acceptances until March 6.

On the AIM market, Avacta rose 15% as it noted press speculation about UK government take-up of its lateral flow SARS-CoV-2 rapid antigen test.

"The company is now progressing to a full clinical validation with a larger number of patient samples in order to obtain a CE mark for the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year," Avacta said.

The biotechnology company added that press reports which stated a saliva-based rapid antigen test is being developed at its Porton Down facility in Wiltshire are incorrect.

Avacta added: "In fact, the evaluated test was the anterior nasal swab test that has subsequently generated the excellent initial clinical performance data.

"We believe an accurate, rapid antigen test, that has been appropriately validated, will help to limit the spread of the coronavirus and support the safe return to work and play. In the UK, the Department of Health & Social Care is a potential customer and partner in the roll out of such a validated test."

Brent oil was quoted at USD63.34 a barrel, down slightly from USD63.47 at the London equities close Friday. Safe-haven gold was quoted at USD1,791.44 an ounce, up from USD1,786.45.

By Eric Cunha; ericcunha@alliancenews.com;

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
19 Dec 2023 09:57

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.

Read more
13 Dec 2023 11:49

Avacta says study shows cancer treatment AVA6000 working as planned

(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended.

Read more
13 Dec 2023 07:46

Avacta hails "encouraging" clinical data from cancer-targeting study

(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".

Read more
28 Sep 2023 11:08

IN BRIEF: Avacta loss widens on cost rise but clinical tests positive

Avacta Group PLC - Wetherby, England-based life sciences company that develops targeted oncology drugs and diagnostics - Pretax loss widens to GBP12.8 million in the six months that ended June 30 from GBP9.7 million a year before. Revenue doubles to GBP11.9 million from GBP5.5 million, but selling, general and administrative expenses near double as well, to GBP8.6 million from GBP4.7 million. Research costs are steady at GBP6.0 million. Has GBP26.0 million cash, up from GBP17.0 million a year before, though down from GBP41.8 million on December 31. Highlights success of AVA6000, a chemotherapy drug for cancer patients, in a Phase 1a clinical study. Avacta aims to complete a dose escalation safety study and provide results during the fourth quarter.

Read more
28 Sep 2023 07:57

Avacta reports higher losses in first half

(Sharecast News) - Cancer treatments and diagnostics group Avacta reported higher losses in the first half despite a doubling of revenues.

Read more
21 Sep 2023 15:48

UK earnings, trading statements calendar - next 7 days

Friday 22 September 
Ascential PLCHalf Year Results
Ergomed PLCHalf Year Results
First Tin PLCHalf Year Results
t42 IoT Tracking Solutions PLCHalf Year Results
t42 IoT Tracking Solutions PLCTrading Statement
Monday 25 September 
Alphawave IP Group PLCHalf Year Results
Devolver Digital IncHalf Year Results
Dialight PLCHalf Year Results
Getech Group PLCHalf Year Results
Ondine Biomedical IncHalf Year Results
Real Estate Investors PLCHalf Year Results
SpaceandPeople PLCHalf Year Results
Spectra Systems CorpHalf Year Results
Transense Technologies PLCFull Year Results
Venture Life Group PLCHalf Year Results
Wilmington PLCFull Year Results
Tuesday 26 September 
Alliance Pharma PLCHalf Year Results
AG Barr PLCHalf Year Results
Animalcare Group PLCHalf Year Results
Asos PLCTrading Statement
Boku IncHalf Year Results
Card Factory PLCHalf Year Results
Cambridge Cognition Holdings PLCHalf Year Results
Close Brothers Group PLCFull Year Results
Diaceutics PLCHalf Year Results
DigitalBox PLCHalf Year Results
Dillistone Group PLCHalf Year Results
EKF Diagnostics Holdings PLCHalf Year Results
Ferguson PLCFull Year Results
Finsbury Food Group PLCFull Year Results
IQGeo Group PLCHalf Year Results
Learning Technologies Group PLCHalf Year Results
LifeSafe Holdings PLCHalf Year Results
Mission Group PLCHalf Year Results
Mortgage Advice Bureau Holdings PLCHalf Year Results
NAHL Group PLCHalf Year Results
Next 15 Group PLCHalf Year Results
Newmark Security PLCFull Year Results
NIOX Group PLCHalf Year Results
Origin Enterprises PLCFull Year Results
PZ Cussons PLCFull Year Results
Safestay PLCHalf Year Results
Smiths Group PLCFull Year Results
Time Finance PLCFull Year Results
tinyBuild IncHalf Year Results
Wentworth Resources PLCHalf Year Results
Yu Group PLCHalf Year Results
Wednesday 27 September 
Amicorp FS (UK) PLCHalf Year Results
Aquila European Renewables PLCHalf Year Results
Arix Bioscience PLCHalf Year Results
Avingtrans PLCFull Year Results
Bens Creek Group PLCFull Year Results
Biome Technologies PLCHalf Year Results
BioPharma Credit PLCHalf Year Results
Chapel Down Group PLCHalf Year Results
Everyman Media Group PLCHalf Year Results
Fadel Partners IncHalf Year Results
NCC Group PLCFull Year Results
Old Mutual LtdHalf Year Results
Pantheon Infrastructure PLCHalf Year Results
Pendragon PLCFull Year Results
Plant Health Care PLCHalf Year Results
Safestyle UK PLCHalf Year Results
Saga PLCHalf Year Results
Skillcast Group PLCHalf Year Results
Surface Transforms PLCHalf Year Results
Xeros Technology Group PLCHalf Year Results
Zinc Media Group PLCHalf Year Results
Thursday 28 September 
Atlantic Lithium LtdFull Year Results
Avacta Group PLCHalf Year Results
Avation PLCFull Year Results
Celadon Pharmaceuticals PLCHalf Year Results
Ceres Power Holdings PLCHalf Year Results
Dar Global PLCHalf Year Results
eEnergy Group PLCFull Year Results
HSS Hire Group PLCHalf Year Results
Microlise Group PLCFull Year Results
Novacyt SAHalf Year Results
Phoenix Spree Deutschland LtdHalf Year Results
RBG Holdings PLCHalf Year Results
Shield Therapeutics PLCHalf Year Results
Silver Bullet Data Services Group PLCHalf Year Results
Trellus Health PLCHalf Year Results
Trinity Exploration & Production PLCHalf Year Results
XLMedia PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Sep 2023 14:37

TRADING UPDATES: Capital inks contract; Lansdowne becomes cash shell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Sep 2023 11:57

Avacta brings in clinical consultant as it hunts for permanent CMO

(Sharecast News) - Oncology-focussed life science company Avacta Group announced a new consultancy pact with Dr Christina Coughlin on Tuesday.

Read more
19 Sep 2023 13:39

Avacta upbeat on fresh data from chemotherapy trial

(Sharecast News) - Life sciences company Avacta Group announced the successful completion of its sixth dose escalation cohort in the ALS-6000-101 phase one clinical trial on Tuesday, assessing the safety and tolerability of the drug, AVA6000.

Read more
19 Sep 2023 13:36

Avacta notes "excellent" safety profile for prospective sarcoma drug

(Alliance News) - Avacta Group PLC on Tuesday said it successfully completed the sixth dose escalation of the ALS-6000-101 phase 1 clinical trial, in which its AVA6000 soft tissue sarcoma treatment demonstrated an "excellent" safety profile.

Read more
21 Jul 2023 16:00

IN BRIEF: Avacta Group issues 3.8 million shares to make repayment

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Issues 3.8 million new shares of 10 pence each to settle quarterly principal of GBP2.6 million and interest repayment of GBP760,000. After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by GBP2.6 million to GBP44.2 million.

Read more
21 Jun 2023 15:43

UK shareholder meetings calendar - next 7 days

Thursday 22 June 
Alphawave IP Group PLCAGM
Angling Direct PLCAGM
Anglo Asian Mining PLCAGM
boohoo Group PLCAGM
Braime Group PLCAGM
Card Factory PLCAGM
Ergomed PLCAGM
Falcon Oil & Gas LtdAGM
Futura Medical PLCAGM
Good Energy Group PLCAGM
Grand Vision Media Holdings PLCAGM
Longboat Energy PLCAGM
MaxRets Ventures PLCAGM
Pathfinder Minerals PLCAGM
RBG Holdings PLCAGM
Robinson PLCAGM
Sanderson Design Group PLCAGM
Team17 Group PLCAGM
Trellus Health PLCAGM
Whitbread PLCAGM
Friday 23 June 
Cadogan Petroleum PLCAGM
Mears Group PLCAGM
Non-Standard Finance PLCAGM
Ocean Harvest Technology Group PLCAGM
Oxford Biomedica PLCAGM
Pelatro PLCAGM
Petrofac LtdAGM
Princess Private Equity Holding LtdAGM
Rathbones Group PLCGM re agreement regarding all-share combination with Invested Wealth & Investment Ltd
Supply@Me Capital PLCGM re open offer warrant holders
Vietnam Enterprise Investments LtdAGM
VPC Specialty Lending Investments PLCAGM
Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
21 Jun 2023 13:53

Avacta completes fifth dose escalation in chemotherapy trial

(Sharecast News) - Life sciences company Avacta announced the successful completion of the fifth dose escalation cohort in the phase 1 clinical trial for AVA6000 on Wednesday.

Read more
21 Jun 2023 09:58

Avacta says AVA6000 fifth dose escalation results "very favourable"

(Alliance News) - Avacta Group PLC on Wednesday said it has completed the fifth dose escalation cohort in its phase 1 clinical study of AVA6000.

Read more
19 Jun 2023 12:43

IN BRIEF: Avacta says no fundraising imminent after market speculation

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Reponds to recent market speculation regarding a possible fundraising. Says no fundraising is imminent. Notes it has a strong cash balance of GBP27 million as at May 31 and expects strong new flow in the company months.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.